World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
34937
World Ranking
14883
National Ranking
169

Overview

Stephen L. Chan is affiliated with the Chinese University of Hong Kong in China. Their research primarily focuses on Medicine, with particular emphasis on Hepatology, Oncology, Epidemiology, Pulmonary and Respiratory Medicine, and Surgery.

The main topics in their body of work include hepatocellular carcinoma treatment and prognosis, liver disease diagnosis and treatment, cancer immunotherapy and biomarkers, pancreatic and hepatic oncology research, cholangiocarcinoma and gallbladder cancer studies, cancer mechanisms and therapy, and colorectal cancer treatments and studies.

Frequent publication venues for their research include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepatology
  • Liver Cancer
  • Cancer Research

Stephen L. Chan has collaborated frequently with the following co-authors:

  • Masatoshi Kudo
  • Bruno Sangro
  • Lorenza Rimassa
  • Ann-Lii Cheng
  • Landon L. Chan

Recent papers authored or co-authored by them include:

  • Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, 2022, NEJM Evidence
  • Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma, 2020, Journal of Hepatology
  • Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study, 2023, The Lancet
  • Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial, 2022, The Lancet Oncology

Best Publications

  • Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Philip J. Johnson;Sarah Berhane;Chiaki Kagebayashi;Shinji Satomura

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Tim Meyer;Ann Lii Cheng;Anthony B. El-Khoueiry

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments.

    Kun Sun;Peiyong Jiang;K. C. Allen Chan;John Wong

  • Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

    Peiyong Jiang;Carol W.M. Chan;K. C.Allen Chan;Suk Hang Cheng

  • Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.

    K C Allen Chan;John K S Woo;Ann King;Benny C Y Zee

  • Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

    Stephen Chan;Max E. Scheulen;Stephen Johnston;Klaus Mross

  • Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing

    K. C.Allen Chan;Peiyong Jiang;Yama W.L. Zheng;Gary J.W. Liao

  • Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers

    Vincent Wai Sun Wong;Stephen Lam Chan;Frankie Mo;Tung Ching Chan

  • Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing

    K. C. Allen Chan;Peiyong Jiang;Carol W. M. Chan;Kun Sun

  • Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

    Peter R Galle;Friedrich Foerster;Masatoshi Kudo;Stephen L Chan

  • Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

    Ann-Lii Cheng;Chiun Hsu;Stephen L. Chan;Su-Pin Choo

  • Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

    Tomasz Burzykowski;Marc Buyse;Martine J. Piccart-Gebhart;George Sledge

  • High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.

    Henry Lik Yuen Chan;Chi Hang Tse;Frankie Mo;Jane Koh

  • New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

    Stephen L. Chan;Frankie K.F. Mo;Philip J. Johnson;Edwin P. Hui

  • Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

    Peter Schmid;Jacinta Abraham;Stephen Chan;Duncan Wheatley

  • Systemic treatment of hepatocellular carcinoma: An EASL position paper

    Jordi Bruix;Stephen L. Chan;Peter R. Galle;Lorenza Rimassa

  • Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

    Martine J. Piccart-Gebhart;Tomasz Burzykowski;Marc Buyse;George Sledge

  • Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Sarah Berhane;Hidenori Toyoda;Toshifumi Tada;Takashi Kumada

Frequent Co-Authors

Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
Anthony T.C. Chan
Anthony T.C. Chan Chinese University of Hong Kong
Anthony W.H. Chan
Anthony W.H. Chan Chinese University of Hong Kong
Paul B.S. Lai
Paul B.S. Lai Chinese University of Hong Kong
Ka-Fai To
Ka-Fai To Chinese University of Hong Kong
Masatoshi Kudo
Masatoshi Kudo Kindai University
Tony Mok
Tony Mok Chinese University of Hong Kong
John Wong
John Wong University of Hong Kong
Vincent Wai-Sun Wong
Vincent Wai-Sun Wong Chinese University of Hong Kong
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options can help prospective and current medical students find flexible, accelerated pathways into healthcare careers. For registered nurses looking to advance their qualifications, choosing an rn to bsn online with no clinicals can save time and allow for a smoother transition without being tied to on-site clinical requirements.

Those aiming for the highest levels of nursing leadership might consider the shortest msn to dnp program to fast-track their credentials. Additionally, convenience can be maximized by searching for dnp programs without dissertation, removing a traditional academic hurdle while maintaining strong clinical and leadership training.

Individuals starting their healthcare journey might benefit from a 6 month lpn program, getting them into the workforce quickly and providing a stepping stone to further studies. These pathways highlight the growing accessibility and variety of online healthcare degrees, making it easier to find a program that meets your professional goals and schedule.

Best Scientists Citing Stephen L. Chan

Trending Scientists